trending Market Intelligence /marketintelligence/en/news-insights/trending/0W2rFjTOUblr2ynXDm4Ehw2 content esgSubNav
In This List

OncoSec undertakes 1-for-10 reverse stock split

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


OncoSec undertakes 1-for-10 reverse stock split

Pennington, N.J.-based cancer drug developer OncoSec Medical Inc.'s board approved a 1-for-10 reverse stock split of its common stock, effective May 20.

The move reduced the company's issued and outstanding common shares to about 7 million from approximately 70 million.

OncoSec's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market under the ticker ONCS, effective May 21.